A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

导出 LinkOut

翻译打印收藏纠错

作者： Antje,Prasse ^[1] ; Murali,Ramaswamy ^[2] ; Shaun,Mohan ^[3] ; Lin,Pan ^[3] ; Andrew,Kenwright ^[3] ; Margaret,Neighbors ^[3] ; Paula,Belloni ^[3] ; Peter P,LaCamera ^[4]

作者单位： Hannover Medical School and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany. prasse.antje@mh-hannover.de. ^[1] PulmonIx, LLC, and Cone Health, Greensboro, NC, USA. ^[2] Genentech, Inc., South San Francisco, CA, USA. ^[3] St. Elizabeth's Medical Center, Boston, MA, USA. ^[4]

关键词 Hedgehog signaling pathway Idiopathic pulmonary fibrosis Pirfenidone Safety Tolerability Vismodegib

DOI 10.1007/s41030-019-0096-8

PMID 32026407

发布时间 2020-09-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Pulmonary therapy

2019年5卷2期

151-163页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Pulmonary therapy

相似文献

Pulmonary therapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Pulmonary therapy

相似文献

Pulmonary therapy

相关期刊

检索历史清除